CD44v6 is not a prognostic factor in primary breast cancer

N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: CD44 is an adhesion molecule and represents a highly variable family of isoforms. The isoform CD44v6 has been associated with metastasis formation and poor prognosis in animal models and human colon cancer. Results of studies in primary breast cancer are relatively small and contradictory. Patients and methods: The immunohistochemical expression of CD44v6 was studied in a series of 338 patients with primary breast tumors, uniformly staged and treated in a single center with a long median follow-up of 128 months. The prognostic significance of CD44v6 as well as the correlation with several clinicopathological features were analysed. Results: Two hundred nineteen of 338 (64.8%) of the breast cancers were CD44v6- positive (> 5% of tumour cells with positive staining), CD44v6 expression had no value for prognosticating disease-free or overall survival at this or any other cut-off point. Conclusion: CD44v6 expression is not a prognostic factor in primary breast cancer.

Cite

CITATION STYLE

APA

Jansen, R. H. L., Joosten-Achjanie, S. R., Arends, J. W., AVolovics, Hupperets, P. S. G. J., Schouten, H. C., & Hillen, H. F. P. (1998). CD44v6 is not a prognostic factor in primary breast cancer. Annals of Oncology, 9(1), 109–111. https://doi.org/10.1023/A:1008220917687

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free